[Improvement of surgical outcomes in patients with prostatic adenoma due to postoperative administration of the drug likoprofit].
We studied efficacy and safety of likoprofit pharmacotherapy in patients early after transurethral resection (TUR) of the prostate. The drug was well tolerated--no withdrawals were noted. Likoprofit showed high efficacy early after TUR for prostatic adenoma in correction of irritative disorders of urination (frequent voiding, urges, painful urination with small urine portions). This means a significant improvement in quality of life in patients after TUR.